SOURCE: The Medicines Company

The Medicines Company

August 10, 2009 07:00 ET

The Medicines Company Responds to Incorrect News Reports

PARSIPPANY, NJ--(Marketwire - August 10, 2009) - The Medicines Company (NASDAQ: MDCO) announced today that it had responded to inaccurate implications in a column in The New York Times on August 9, 2009 by Frank Rich and a report that aired on Rachel Maddow's news show on MSNBC on August 6, 2009. The column and report both contained statements that incorrectly created the impression that The Medicines Company has engaged lobbyists to oppose pending healthcare reform legislation and supported efforts to disrupt debate about health care reform. Neither implication is accurate. The Medicines Company has not opposed any of the pending health care reform bills, and has not in any way supported any efforts to disrupt open debate about health care reform. The company's lobbying efforts relate solely to a change in the U.S. patent laws to enable more research, innovation and cost saving in health care. The Medicines Company sincerely hopes that The New York Times and MSNBC, both respected news outlets, will correct their stories.

About The Medicines Company

The Medicines Company (NASDAQ: MDCO) is focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. The Company markets Angiomax® (bivalirudin) in the United States and other countries for use in patients undergoing coronary angioplasty, and Cleviprex® (clevidipine butyrate) injectable emulsion in the United States for the reduction of blood pressure when oral therapy is not feasible or not desirable. The Company also has two products in late stage development, cangrelor, an investigational antiplatelet agent and oritavancin, a semi-synthetic lipoglycopeptide antibiotic currently awaiting EU regulatory approval. The Company's pipeline also includes a serine protease inhibitor, CU2010, in early-stage development. The Medicines Company's website is www.themedicinescompany.com.

Cautionary Note Regarding Forward-Looking Statements

Statements contained in this press release about The Medicines Company that are not purely historical, and all other statements that are not purely historical, may be deemed to be forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, the words "believes," "anticipates," "expects" and "estimates" and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. Important factors that may cause or contribute to such differences include: whether the Company will be able to obtain regulatory approvals; whether the Company's products and product candidates will advance in the clinical trial process on a timely basis or at all; whether clinical trial results will warrant submission of applications for regulatory approval; whether physicians, patients and other key decision-makers will accept clinical trial results; whether the Company will be able to successfully distribute and market its approved products; and such other factors as are set forth in the risk factors detailed from time to time in the Company's periodic reports and registration statements filed with the Securities and Exchange Commission including, without limitation, the risk factors detailed in the Company's Annual Report on Form 10-Q filed on May 11, 2009, which are incorporated herein by reference. The Company specifically disclaims any obligation to update these forward-looking statements.

Contact Information